A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

Thomas C. Heineman, Mary Lou Clements-Mann, Gregory A. Poland, Robert M. Jacobson, Allen E. Izu, Doreen Sakamoto, Joseph Eiden, Gary A. Van Nest, Henry H. Hsu

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

The safety and immunogenicity of a novel hepatitis B virus (HBV) vaccine containing recombinant PreS2 and S antigens combined with MF59 adjuvant (HBV/MF59) was evaluated in healthy adults (N = 230) who were randomized to receive 2 or 3 immunizations of either the study vaccine or a licensed control vaccine (Recombivax HB®). After a single immunization, 105 of 118 (89%) recipients of HBV/MF59 achieved protective serum levels of anti-HBs antibody (> 10 mIU/ml), compared with 13 of 110 (12%) recipients of licensed vaccine (P < 0.001). The geometric mean titer (GMT) after 2 doses of HBV/MF59 given 2 months apart (13,422 mIU/ml) was more than 5-fold higher than that following 3 doses of licensed vaccine given over 6 months (2,346 mIU/ml; P < 0.001). The GMT following 3 injections of HBV/MF59 (249,917 mIU/ml) was 100- fold higher than licensed vaccine (P < 0.001). Anti-PreS2 antibodies were elicited in over 90% of the subset of HBV/MF59 recipients tested. Both vaccines were well tolerated; transient, mild-to-moderate local inflammation was the major postinjection reaction.

Original languageEnglish (US)
Pages (from-to)2769-2778
Number of pages10
JournalVaccine
Volume17
Issue number22
DOIs
StatePublished - Jul 16 1999

Fingerprint

Hepatitis B Vaccines
hepatitis B
Hepatitis B virus
adjuvants
Vaccines
immune response
vaccines
Anti-Idiotypic Antibodies
Immunization
immunization
antibodies
dosage
MF59 oil emulsion
Inflammation
Safety
inflammation
Antigens
Injections
injection
antigens

Keywords

  • Adjuvant
  • Clinical trials
  • Hepatitis B vaccine
  • Immunologic

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Heineman, T. C., Clements-Mann, M. L., Poland, G. A., Jacobson, R. M., Izu, A. E., Sakamoto, D., ... Hsu, H. H. (1999). A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine, 17(22), 2769-2778. https://doi.org/10.1016/S0264-410X(99)00088-2

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. / Heineman, Thomas C.; Clements-Mann, Mary Lou; Poland, Gregory A.; Jacobson, Robert M.; Izu, Allen E.; Sakamoto, Doreen; Eiden, Joseph; Van Nest, Gary A.; Hsu, Henry H.

In: Vaccine, Vol. 17, No. 22, 16.07.1999, p. 2769-2778.

Research output: Contribution to journalArticle

Heineman, TC, Clements-Mann, ML, Poland, GA, Jacobson, RM, Izu, AE, Sakamoto, D, Eiden, J, Van Nest, GA & Hsu, HH 1999, 'A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant', Vaccine, vol. 17, no. 22, pp. 2769-2778. https://doi.org/10.1016/S0264-410X(99)00088-2
Heineman TC, Clements-Mann ML, Poland GA, Jacobson RM, Izu AE, Sakamoto D et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine. 1999 Jul 16;17(22):2769-2778. https://doi.org/10.1016/S0264-410X(99)00088-2
Heineman, Thomas C. ; Clements-Mann, Mary Lou ; Poland, Gregory A. ; Jacobson, Robert M. ; Izu, Allen E. ; Sakamoto, Doreen ; Eiden, Joseph ; Van Nest, Gary A. ; Hsu, Henry H. / A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. In: Vaccine. 1999 ; Vol. 17, No. 22. pp. 2769-2778.
@article{351d85bbb45442a39da362b6c57144fd,
title = "A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant",
abstract = "The safety and immunogenicity of a novel hepatitis B virus (HBV) vaccine containing recombinant PreS2 and S antigens combined with MF59 adjuvant (HBV/MF59) was evaluated in healthy adults (N = 230) who were randomized to receive 2 or 3 immunizations of either the study vaccine or a licensed control vaccine (Recombivax HB{\circledR}). After a single immunization, 105 of 118 (89{\%}) recipients of HBV/MF59 achieved protective serum levels of anti-HBs antibody (> 10 mIU/ml), compared with 13 of 110 (12{\%}) recipients of licensed vaccine (P < 0.001). The geometric mean titer (GMT) after 2 doses of HBV/MF59 given 2 months apart (13,422 mIU/ml) was more than 5-fold higher than that following 3 doses of licensed vaccine given over 6 months (2,346 mIU/ml; P < 0.001). The GMT following 3 injections of HBV/MF59 (249,917 mIU/ml) was 100- fold higher than licensed vaccine (P < 0.001). Anti-PreS2 antibodies were elicited in over 90{\%} of the subset of HBV/MF59 recipients tested. Both vaccines were well tolerated; transient, mild-to-moderate local inflammation was the major postinjection reaction.",
keywords = "Adjuvant, Clinical trials, Hepatitis B vaccine, Immunologic",
author = "Heineman, {Thomas C.} and Clements-Mann, {Mary Lou} and Poland, {Gregory A.} and Jacobson, {Robert M.} and Izu, {Allen E.} and Doreen Sakamoto and Joseph Eiden and {Van Nest}, {Gary A.} and Hsu, {Henry H.}",
year = "1999",
month = "7",
day = "16",
doi = "10.1016/S0264-410X(99)00088-2",
language = "English (US)",
volume = "17",
pages = "2769--2778",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "22",

}

TY - JOUR

T1 - A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

AU - Heineman, Thomas C.

AU - Clements-Mann, Mary Lou

AU - Poland, Gregory A.

AU - Jacobson, Robert M.

AU - Izu, Allen E.

AU - Sakamoto, Doreen

AU - Eiden, Joseph

AU - Van Nest, Gary A.

AU - Hsu, Henry H.

PY - 1999/7/16

Y1 - 1999/7/16

N2 - The safety and immunogenicity of a novel hepatitis B virus (HBV) vaccine containing recombinant PreS2 and S antigens combined with MF59 adjuvant (HBV/MF59) was evaluated in healthy adults (N = 230) who were randomized to receive 2 or 3 immunizations of either the study vaccine or a licensed control vaccine (Recombivax HB®). After a single immunization, 105 of 118 (89%) recipients of HBV/MF59 achieved protective serum levels of anti-HBs antibody (> 10 mIU/ml), compared with 13 of 110 (12%) recipients of licensed vaccine (P < 0.001). The geometric mean titer (GMT) after 2 doses of HBV/MF59 given 2 months apart (13,422 mIU/ml) was more than 5-fold higher than that following 3 doses of licensed vaccine given over 6 months (2,346 mIU/ml; P < 0.001). The GMT following 3 injections of HBV/MF59 (249,917 mIU/ml) was 100- fold higher than licensed vaccine (P < 0.001). Anti-PreS2 antibodies were elicited in over 90% of the subset of HBV/MF59 recipients tested. Both vaccines were well tolerated; transient, mild-to-moderate local inflammation was the major postinjection reaction.

AB - The safety and immunogenicity of a novel hepatitis B virus (HBV) vaccine containing recombinant PreS2 and S antigens combined with MF59 adjuvant (HBV/MF59) was evaluated in healthy adults (N = 230) who were randomized to receive 2 or 3 immunizations of either the study vaccine or a licensed control vaccine (Recombivax HB®). After a single immunization, 105 of 118 (89%) recipients of HBV/MF59 achieved protective serum levels of anti-HBs antibody (> 10 mIU/ml), compared with 13 of 110 (12%) recipients of licensed vaccine (P < 0.001). The geometric mean titer (GMT) after 2 doses of HBV/MF59 given 2 months apart (13,422 mIU/ml) was more than 5-fold higher than that following 3 doses of licensed vaccine given over 6 months (2,346 mIU/ml; P < 0.001). The GMT following 3 injections of HBV/MF59 (249,917 mIU/ml) was 100- fold higher than licensed vaccine (P < 0.001). Anti-PreS2 antibodies were elicited in over 90% of the subset of HBV/MF59 recipients tested. Both vaccines were well tolerated; transient, mild-to-moderate local inflammation was the major postinjection reaction.

KW - Adjuvant

KW - Clinical trials

KW - Hepatitis B vaccine

KW - Immunologic

UR - http://www.scopus.com/inward/record.url?scp=0033575487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033575487&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(99)00088-2

DO - 10.1016/S0264-410X(99)00088-2

M3 - Article

VL - 17

SP - 2769

EP - 2778

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 22

ER -